Efficacy and Safety of ACH24 in the Treatment of Vitiligo

Inclusion Criteria: * Patients of both sexes, aged between 18 and 65 years, remaining the feasibility of a legal guardian in accordance with need, able to understand and provide written informed consent and able to allow compliance at the treatment and the requirements of the protocol; * Presence of generalized vitiligo; * Able to comprehend and willing to provide written informed consent in accordance with institutional and regulatory guidelines. Exclusion Criteria: * Patients with: * Inflammatory diseases; * Alopecia Areata; * Diabetes Type I; * Asthma; * Collagen disease; * Atopic dermatitis; * Psoriasis; * Autoimmune thyroid disease (self reported). ¬ Thyroid problems (represents 15% of people with vitiligo), exclude only those who need to do treatment with corticosteroid or immunosuppressive. * Women of childbearing age who had tested positive for pregnancy, or who do not use acceptable contraceptive method, or do not agree to practice reliable contraception during the study; * Woman in pregnancy or lactation period; * Known allergic reaction against the phytomedicine as assessed by medical history; * Patient that is taking any prohibited medication (Item 9.3); * Participation in last one year of clinical protocols, unless it can be direct benefit to subject; * Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (eg, blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy t…